Cell and gene therapy manufacturing is, in many ways, incompatible with traditional bulk manufacturing methods, which were designed for a uniform product that is “made-to-stock.” All the ...

The news led to a stock surge on expectations that forthcoming data for the company’s experimental gene therapy for Rett ...

Gene therapy ... or universal, cell therapies to treat cancer. The stock took a big hit in March when the company announced it is pausing development of allogeneic cell therapy CB-020.

The first gene therapy was approved ... Today, there are 27 approved gene and cell therapies in the U.S. and more than 2,300 in clinical trials. Sign up for stock news with our Invested newsletter.

Image source ... Several gene-editing companies are also targeting various types of cancer. In particular, CRISPR is being used to develop chimeric antigen receptor (CAR) T-cell therapies where ...

Shares of Editas Medicine EDIT plunged 12.5% on Tuesday after announcing that it is seeking a global partner to advance its ...

Beam Therapeutics (BEAM) stock falls as patient dies after receiving the company's gene editing therapy.in an early-stage ...

READ ALSO: 10 Most Promising Biotech Stocks According to Hedge Funds. The cell and gene therapy sector has faced significant investment challenges since the boom years of 2020 and 2021.

CRISPR Therapeutics (NASDAQ:CRSP) stock rose 5% on news that the U.K. gave conditional marketing authority to its gene therapy for sickle cell anemia. It’s the first authorization in the world ...

READ ALSO: 10 Most Promising Biotech Stocks According to Hedge Funds. The cell and gene therapy sector has faced significant investment challenges since the boom years of 2020 and 2021.

Beam Therapeutics (BEAM) stock gains as Leerink upgrades the biotech despite a fatality in a gene editing study, citing an ...

FDA decision day nears for Casgevy, the gene ... cell disease. Crispr shares have risen roughly 80% since the end of October after a favorable FDA advisory committee meeting on the gene therapy.